Neutron Therapeutics

Lumicell is a pioneering company based in Wellesley, MA that is revolutionizing breast cancer surgery with its investigational fluorescence imaging technology. Their system is designed to provide real-time illumination of residual breast cancer during lumpectomy surgery, assisting in the detection of cancerous tissue within the lumpectomy cavity. With the potential to transform the current landscape of breast cancer surgery, Lumicell's transformative technology aims to evolve the standard of care in cancer surgery. Lumicell's innovative approach has garnered attention and recognition, with their co-founder Moungi Bawendi being awarded the Nobel Prize in Chemistry for his expertise in optics, fluorescent molecules, and tissue imaging. The company has also made significant strides in gaining regulatory approval, with the FDA accepting and prioritizing their New Drug Application for the LUMISIGHT Optical Imaging Agent and their Premarket Approval application for the Lumicell Direct Visualization System. Lumicell's commitment to advancing cancer surgery is further demonstrated by their recent appointment of Brent Palmisano as Chief Commercial Officer, as they prepare for the market launch of their groundbreaking technology.Generated from the website

Seaver Construction is a well-regarded general contracting firm located in Woburn, Massachusetts, specializing in both commercial and residential construction projects. With a commitment to providing exceptional construction experiences, the company serves clients across eastern Massachusetts, southern New Hampshire, and southern Maine. Recognized for its quality work, Seaver Construction has established itself as an award-winning leader in the industry. The firm is dedicated to discussing project possibilities and ensuring client satisfaction from start to finish. Generated from the website

Alnylam Pharmaceuticals is a pioneering biopharmaceutical company based in Cambridge, MA, focused on developing RNA interference (RNAi) therapeutics to transform the treatment landscape for diseases by silencing the genes responsible for their progression. Leveraging the body's natural processes, Alnylam aims to deliver targeted medicines that address both rare and prevalent diseases, prioritizing patient needs and their experiences. Driven by a profound commitment to scientific innovation, Alnylam's robust pipeline encompasses various therapeutic areas and reflects its dedication to improving lives through impactful medicines. The company also embraces corporate responsibility, seeking to extend its positive influence beyond medication development by being a supportive force for the communities it serves. Generated from the website